Celldex Therapeutics ditched its glembatumumab vedotin program last week after it failed a phase 2 study in triple-negative breast cancer. Now, the company is laying off 41 employees and choosing not to fill 18 open positions to cut costs and stay afloat.
The reduction will leave the company with 148 employees and come to about $1.3 million in severance-related costs, Celldex said in an SEC filing Tuesday. In addition to slashing operating costs, the move will also “better align its workforce with the needs of its business,” the company said.
New Jersey-based Celldex hit its first major roadblock in 2016, when its cancer vaccine Rintega failed a phase 3 glioblastoma trial. Once predicted to become the second cancer vaccine to earn approval in the U.S. after Provenge, the candidate did not improve survival, leading Celldex to end the trial. It turned to glembatumumab vedotin (glemba), the most advanced asset in its pipeline.
But that blew up too—nearly two years later, history repeated itself and the once-promising glemba also failed to improve survival over Genentech’s Xeloda in patients with metastatic triple-negative breast cancer. Celldex discontinued the program and started “evaluating our operational and workforce needs to extend our financial resources and direct them to continued pipeline advancement,” said CEO Anthony Marucci at the time.
Now, Celldex is left to pick up the pieces with what’s left of its pipeline. Varlilumab, a CD27 agonist, is in a phase 2 study in combination with Bristol-Myers’ Opdivo, with data expected to read out this year. And a phase 2 trial of CDX-3379, an ErbB3 inhibitor, in tandem with Eli Lilly’s Erbitux is set to finish enrolling in the third quarter. That leaves a CD40 agonist and a dendritic cell mobilizer, which are both in phase 1.
By Amirah Al Idrus
Source: Fierce Biotech
The deal will see Microsoft use its capabilities in computational services, cloud computing and artificial intelligence to support drug discovery and development at UCB.
The planned closures come as GSK has agreed to sell its cephalosporins antibiotics business to Sandoz, a division of Swiss pharma firm Novartis, for as much as US$500m.
“The launch of these new formulations provides the nutritional market with much-needed alternative coating systems that address clean label consumer preferences and are easy to implement,” says Kelly Boyer, vice president film coatings at Colorcon.